- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05025488
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
A Phase I Open Label Peptide Based Vaccine in Patients With Myeloproliferative Neoplasm Harboring CALR Mutations
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Current MPN treatments are geared towards symptom palliation and not on changing the natural course of the disease. Mutations in calreticulin gene (CALR) is the second most common driver mutation in ET and MF patients (30%). All CALR mutations identified to date in MPN patients result in the formation of an altered protein with an identical 36-amino acid sequence in the C-terminus. This altered protein results in a MPN-specific shared neo-antigen. The mutated CALR neoantigen present in patient with MPN represents an ideal antigen for targeted immunotherapy as it is stably and specifically expressed by the malignant cells and is absent in the normal tissues. CALR neoantigen is immunogenic, effector T cells are capable of recognizing this neo-antigen, and hematopoietic cells carrying the mutation can be potently killed by these specific effector T-cells in vitro.
The researchers believe that a mutated-CALR vaccine will enhance mutated-CALR-specific T cell immunity in MPN patients carrying CALR mutations, which in turn would target and eliminate CALR+ malignant cells, thereby leading to improved clinical outcomes in this patient population.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Marina Kremyanskaya, MD, PhD
- Phone Number: (212) 241-4106
- Email: marina.kremyanskaya@mssm.edu
Study Contact Backup
- Name: Mikaela Dougherty
- Phone Number: 212-241-8839
- Email: mikaela.dougherty@mssm.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- Recruiting
- Icahn School of Medicine at Mount Sinai
-
Principal Investigator:
- Marina Kremyanskaya, MD, PhD
-
Contact:
- Mikaela Dougherty, BS
- Phone Number: 212-241-8839
- Email: mikaela.dougherty@mssm.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Subjects must be ≥18 years of age at the time of signing the informed consent form.
- Confirmed diagnosis of chronic phase MPN: high risk ET (HU failure/intolerance), low-intermediate 1 (DIPSS 0-1) PMF
- Verified mutation in CALR exon 9
- PS ≤ 2
Adequate organ function:
- Absolute neutrophil count ≥ 1000/mm3
- Platelet count ≥ 50,000/mm3,
- Creatinine ≤ 2.5 mg/dL,
- Total bilirubin ≤ 2 mg/dL, (except in patients with Gilbert Syndrome who can have total bilirubin < 3.0 mg/dL)
- Transaminases 3 times above the upper limits of the institutional normal.
- INR<2 if off of anticoagulation. Patients on anticoagulation therapy with an INR>2 may be enrolled at the discretion of the investigator if have not had any episodes of severe hemorrhage.
- Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to starting study medication and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 4 weeks before prior to first dose of vaccine. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a condom during sexual contact with a female of child bearing potential even if have had a successful vasectomy.
- Ability to understand and the willingness to sign a written informed consent.
- Ability to adhere to the study visit schedule and all protocol requirements
Exclusion Criteria
- Other invasive malignancy in the past 3 years except non-melanoma skin cancer, localized cured prostate cancer and early stage breast cancer on HRT.
- Active autoimmune disease
- Uncontrolled serious infection
- Known immunodeficiency
- Pregnant and breastfeeding women
- Not willing to use contraception
- Current use of immunosuppressive medications including steroids
- Current Ruxolitinib or Fedratinib use
- Current use of hydroxyurea
- Current use of INF (use of anagrelide is permitted)
- Treatment with other experimental drugs
- Any significant psychiatric/medical condition per investigators judgment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CALR mutated
peptide-based vaccine in patients with myeloproliferative neoplasm (myelofibrosis and essential thrombocythemia) with CALR mutations
|
ten (10) doses of Mutant-CALR peptides with KLH as helper peptide (in the first vaccine only).
Mutant-CALR vaccine will administered every 2 weeks for the first 4 doses and then every 4 weeks for additional 6 doses.
Maintenance Treatment The protocol allows for a continued administration of up to four (4) additional Mutant-CALR vaccine and four (4) Poly-ICLC administrations, 12 weeks apart.
ten (10) doses of Poly-ICLC.
Poly-ICLC will be given on weeks 1, 3, 5, 7, 11, 15, 19, 23, 27 and 31.
each Poly-ICLC dose must be given the day after the corresponding Mut-CALR vaccination.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Dose Limiting Toxicity (DLT)
Time Frame: 32 weeks
|
The Dose Limiting Toxicity (DLT) rate, defined as the proportion of patients with at least 1 grade 3 or higher AE considered to be at least possibly related to the treatment with Poly ICLC and CALR vaccines.
|
32 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Adverse Events
Time Frame: Week 32
|
The type, incidence, severity, seriousness, and relatedness of adverse events (AEs) per NCI CTCAE v5.0.
|
Week 32
|
Number of laboratory abnormalities
Time Frame: Baseline through Week 32
|
Number of observations, severity, and relatedness of clinical laboratory tests (hematology, biochemistry)
|
Baseline through Week 32
|
Change in Immune Milieu Composite
Time Frame: Baseline through Weeks 55 or 80
|
Changes in the immune milieu (which is a composite of expression of cytokines, presence of antibodies, alterations in number and phenotype of immune cells and induction of vaccine-specific T cell response) due to the vaccines as compared to baseline values.
|
Baseline through Weeks 55 or 80
|
Change in CALR VAF
Time Frame: Baseline through Weeks 55 or 80
|
The % change in driver mutation burden (CALR VAF) as compared to baseline
|
Baseline through Weeks 55 or 80
|
Proportion of participants who normalize their platelet number
Time Frame: Week 32 and weeks 55 or 80
|
The proportion of patients who normalize their platelet number and/or achieve platelets less than 600 if started with platelet above 600.
|
Week 32 and weeks 55 or 80
|
Proportion of participants achieving response
Time Frame: Baseline and Week 32
|
The proportion of patients achieving response or improvement in their disease status by ELN/IWG criteria for the categories: Complete Response; Partial Response; Clinical Improvement and Stable Disease
|
Baseline and Week 32
|
Myelofibrosis Symptom Assessment Form (MF-SAFv4.0)
Time Frame: Week 32 and weeks 55 or 80
|
The proportion of patients who achieve improvement in quality of life as assessed by the by the Myelofibrosis Symptom Assessment Form.
Each of the items are scored 0 to 10, with total score from 0 to 100, with higher score indicating more symptoms.
|
Week 32 and weeks 55 or 80
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai
- Study Chair: Nina Bhardwaj, MD, PhD, Icahn School of Medicine at Mount Sinai
- Study Chair: Camelia Iancu-Rubin, PhD, Icahn School of Medicine at Mount Sinai
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GCO 17-2449
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Essential Thrombocythemia
-
ShireCompletedEssential Thrombocythemia (ET)Japan
-
ShireCompletedEssential Thrombocythemia (ET)United Kingdom, Italy, Czechia, France, Germany, Greece, Spain, Switzerland
-
ShireCompletedEssential Thrombocythemia (ET)Italy
-
ShireCompletedEssential Thrombocythemia (ET)Japan
-
ShireCompletedEssential ThrombocythaemiaSweden, United Kingdom, Spain
-
ShireCompletedThrombocythemia, HemorrhagicBulgaria, France, Hungary, Poland, Portugal, Serbia
-
PharmaEssentiaMedpace, Inc.; EPS International; Brightech InternationalActive, not recruitingEssential ThrombocythemiaUnited States, Canada, Korea, Republic of, China, Hong Kong, Singapore, Taiwan, Japan
-
AOP Orphan Pharmaceuticals AGCompletedEssential ThrombocythaemiaPoland, Slovakia, Bulgaria, Russian Federation, Romania, Croatia, Lithuania, Austria, Ukraine
-
AOP Orphan Pharmaceuticals AGCompletedEssential ThrombocythaemiaAustria, Czech Republic, France, Germany, Hungary, Italy, Lithuania, Poland, Singapore, Slovenia
Clinical Trials on Peptide-based vaccine
-
The First Affiliated Hospital of Nanchang UniversityShanghai Dengding BioAI Co.RecruitingAdvanced Malignant Solid TumorsChina
-
National Liver Institute, EgyptUnknownVaccine Overdose of Undetermined IntentEgypt
-
National Cancer Institute (NCI)CompletedStage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin MelanomaUnited States
-
Abbott NutritionCompletedGastrointestinal Diseases | Feeding IntoleranceCanada
-
Federal Budgetary Research Institution State Research...CompletedCovid19Russian Federation
-
COL George Peoples, MD, FACSCompletedOvarian Cancer | Endometrial Cancer | Peritoneal Cancer | Fallopian CancerUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...RecruitingNSCLC Stage IV | ALK Fusion Protein ExpressionUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage IV Breast Cancer | HER2/Neu Positive | HLA-A2 Positive Cells Present | Stage IV Ovarian CancerUnited States
-
zeinab ahmed yousif hasan ashourRecruiting
-
Herbert LyerlyRecruiting